X4 PHARMACEUTICALS, INC Unrecognized Tax Benefits, Increase Resulting from Acquisition
X4 PHARMACEUTICALS, INC (XFOR) reported Unrecognized Tax Benefits, Increase Resulting from Acquisition of $100.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2024-03-21.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition · last filed 2024-03-21
- X4 PHARMACEUTICALS, INC unrecognized tax benefits, increase resulting from acquisition for fiscal 2021 was $100.00K, a 0.00% change from fiscal 2020.
- X4 PHARMACEUTICALS, INC unrecognized tax benefits, increase resulting from acquisition for fiscal 2020 was $100.00K, a 50.00% decline from fiscal 2019.
- X4 PHARMACEUTICALS, INC unrecognized tax benefits, increase resulting from acquisition for fiscal 2019 was $200.00K.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Acquisition 12 month |
|---|---|
| 2021-12-31 | $100.00K 10-K · filed 2024-03-21 |
| 2020-12-31 | $100.00K 10-K · filed 2022-03-17 |
| 2019-12-31 | $200.00K 10-K · filed 2021-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |